(Total Views: 844)
Posted On: 12/20/2020 9:53:15 AM
Post# of 153984
Pretty impressive from UCLA eind patients .
The status of participants was assessed at 30 days after the first dose of leronlimab (Supplementary Table 1). Defining recovery as survival and no longer being hospitalized, 17 of 23 (74%) were recovered, of whom 1 still required supplemental oxygen (1 L/min). Two of 23 (9%) were still alive but remained hospitalized, and 4 of 23 (17%) had died. Examining the subset of 7 patients who were intubated at the time of leronlimab treatment initiation, 4 of 7 (57%) were recovered and required no supplemental oxygen, while 2 of 7 (29%) were alive but remained hospitalized and 1 of 7 (14%) had died. The 2 initially intubated patients who were still hospitalized on day 30 eventually stabilized and were discharged from the hospital breathing spontaneously.
The status of participants was assessed at 30 days after the first dose of leronlimab (Supplementary Table 1). Defining recovery as survival and no longer being hospitalized, 17 of 23 (74%) were recovered, of whom 1 still required supplemental oxygen (1 L/min). Two of 23 (9%) were still alive but remained hospitalized, and 4 of 23 (17%) had died. Examining the subset of 7 patients who were intubated at the time of leronlimab treatment initiation, 4 of 7 (57%) were recovered and required no supplemental oxygen, while 2 of 7 (29%) were alive but remained hospitalized and 1 of 7 (14%) had died. The 2 initially intubated patients who were still hospitalized on day 30 eventually stabilized and were discharged from the hospital breathing spontaneously.
(2)
(0)
